Literature DB >> 14680820

Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes.

Reinhard E Marks1, Allen W Ho, Fabiola Rivas, Emily Marshall, Sujit Janardhan, Thomas F Gajewski.   

Abstract

Ras can become activated via multiple distinct receptors in T lymphocytes. However, mechanistic studies of Ras signaling in normal T cells have been hampered by the lack of an efficient technology for gene transfer into resting post-thymic cells. We have overcome this limitation by utilizing adenoviral transduction of T cells from Coxsackie/adenovirus receptor transgenic mice. Unexpectedly, dominant negative Ras17N blocked activation of Ras and ERK in response to IL-2R engagement but not TCR/CD3 ligation. However, TCR-induced ERK activation was suppressed by inhibitors of PKC and PLC-gamma. This first biochemical study of DN Ras in normal quiescent T cells reveals a striking contrast in Ras signaling via two receptors, and suggests that the principal mechanism of TCR-induced Ras activation in normal T cells may be distinct from that utilized in T-lineage tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14680820     DOI: 10.1016/j.bbrc.2003.10.168

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  An adenoviral vector for probing promoter activity in primary immune cells.

Authors:  Pulak Tripathi; Rajat Madan; Claire Chougnet; Senad Divanovic; Xiaojing Ma; Larry M Wahl; Thomas Gajewski; Christopher L Karp; David A Hildeman
Journal:  J Immunol Methods       Date:  2006-02-20       Impact factor: 2.303

2.  Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.

Authors:  Reinhard E Marks; Allen W Ho; Christian Robbel; Todd Kuna; Seth Berk; Thomas F Gajewski
Journal:  Blood       Date:  2007-06-01       Impact factor: 22.113

3.  High TCR stimuli prevent induced regulatory T cell differentiation in a NF-κB-dependent manner.

Authors:  Luciana L Molinero; Michelle L Miller; César Evaristo; Maria-Luisa Alegre
Journal:  J Immunol       Date:  2011-03-16       Impact factor: 5.422

4.  Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction.

Authors:  Frederick L Locke; Yuan-yuan Zha; Yan Zheng; Gregory Driessens; Thomas F Gajewski
Journal:  J Immunol       Date:  2013-07-12       Impact factor: 5.422

Review 5.  Key role of ERK pathway signaling in lupus.

Authors:  Gabriela Gorelik; Bruce Richardson
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

6.  An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.

Authors:  Yuanyuan Zha; Thomas F Gajewski
Journal:  Cell Immunol       Date:  2007-09-25       Impact factor: 4.868

7.  Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells.

Authors:  Yuanyuan Zha; Ramila Shah; Frederick Locke; Austin Wong; Thomas F Gajewski
Journal:  J Immunol Methods       Date:  2007-12-26       Impact factor: 2.303

Review 8.  Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells.

Authors:  Robert L Kortum; Alexandre K Rouquette-Jazdanian; Lawrence E Samelson
Journal:  Trends Immunol       Date:  2013-03-15       Impact factor: 16.687

9.  The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for viral replication.

Authors:  Laurence Colin; Nathalie Vandenhoudt; Stéphane de Walque; Benoît Van Driessche; Anna Bergamaschi; Valérie Martinelli; Thomas Cherrier; Caroline Vanhulle; Allan Guiguen; Annie David; Arsène Burny; Georges Herbein; Gianfranco Pancino; Olivier Rohr; Carine Van Lint
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

10.  Primary murine CD4+ T cells fail to acquire the ability to produce effector cytokines when active Ras is present during Th1/Th2 differentiation.

Authors:  Sujit V Janardhan; Reinhard Marks; Thomas F Gajewski
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.